Dowell SF,Butler JC,Giebink GS, et al.Acute otitis media: management and surveillance in an era of pneumococcal resistance—a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.Pediatr Infect Dis J. 1999;18:1-9
4.
Gwaltney JM,Phillips CD,Miller RD, et al.Computed tomographic study of the common cold.N Engl J Med. 1994;330:25-30
5.
Berg O,Carenfelt C,Rystedt G, et al.Occurrence of asymptomatic sinusitis in common cold and other acute ENT-infections.Rhinology. 1986;24:223-5
6.
Scott LevinTM Prescription Audit from Verispan, L.L.C., January-December 2002
7.
Ray NF,Baraniuk JN,Thamer M, et al.Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders.J Allergy Clin Immunol. 1999;103:408-14
8.
Physician Drug & Diagnosis Audit (PDDA) and SourceTM Prescription Audit (SPA) from Verispan, L.L.C., January-December 2002
9.
Gonzales R,Steiner JF,Lum A, et al.Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults.JAMA. 1999;281:1512-9
10.
Dosh SA,Hickner JM,Mainous AG, et al.Predictors of antibiotic prescribing for nonspecific upper respiratory infections, acute bronchitis, and sinusitis.J Fam Pract. 2000;49:407-14
11.
Nissinen A,Gronroos P,Huovinen P.Development of b-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993.Clin Infect Dis. 1995;21:1193-6
12.
Arason V,Kristinsson K,Sigurdsson J, et al.Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study.BMJ. 1996;313:387-91
13.
Seppala H,Klaukka T,Lehtonen R, et al.Outpatient use of erythromycin: link to increased erythromycin resistance in Group A Streptococci.Clin Infect Dis. 1995;:1378-85
14.
Seppala H,Klaukka T,Vuopio-Varkila J, et al.The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland.N Engl J Med. 1997;337:441-6
15.
Hyde TB,Gay K,Stephens DS, et al.Macrolide resistance among invasive Streptococcus pneumoniae isolates.JAMA. 2001;286:1857-62
16.
Baquero F,Martinez-Beltran J,Loza E.A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe.J Antimicrob Chemother. 1991;28 ((Suppl C)): 31-8
17.
McCaig LF,Besser RE,Hughes JM.Antimicrobial drug prescriptions in ambulatory care settings, United States, 1992-2000.Emerg Infect Dis. 2003;9:432-7
18.
McCaig LF,Besser RE,Hughes JM.Trends in antimicrobial prescribing rates for children and adolescents.JAMA. 2002;287:3096-102
19.
Lanza DC,Kennedy DW.Adult rhinosinusitis defined.Otolaryngol Head Neck Surg. 1997;117:S1-7
20.
Diagnosis and treatment of acute bacterial rhinosinusitis.. Rockville, MD: Agency for Health Care Policy and Research; 1999:
21.
Makela MJ,Puhakka T,Ruuskanen O, et al.Viruses and bacteria in the etiology of the common cold.J Clin Microbiol. 1998;36:539-42
22.
Winther B,Gwaltney JM,Mygind N, et al.Viral-induced rhinitis.Am J Rhinol. 1998;12:17-20
23.
Greve JM,Davis G,Meyer AM, et al.The major human rhinovirus receptor is ICAM-1.Cell. 1989;56:839-47
24.
Patel J,Faden H,Sharma S, et al.Effect of respiratory syncytial virus on adherence, colonization and immunity of non-typable Haemophilus influenzae: implications for otitis media.Int J Pediatr Otorhinolaryngol. 1992;23:15-23
25.
AddersonEEUlettGCAvadhanulaV. Respiratory syncytial virus enhanced attachment of nontypeable Haemophilus influenzae to A549 epithelial cells [presentation B-797]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, Illinois
26.
Gwaltney JM,Hendley JO,Simon G, et al.Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response.JAMA. 1967;202:494-500
27.
Gwaltney JM,Hendley JO,Phillips CD, et al.Nose blowing propels nasal fluid into the paranasal sinuses.Clin Infect Dis. 2000;30:387-91
28.
Monto AS,Ullman BM.Acute respiratory illness in an American community. The Tecumseh study.JAMA. 1974;227:164-9
29.
Wald ER,Guerra N,Byers C.Upper respiratory tract infections in young children: duration of and frequency of complications.Pediatrics. 1991;87:129-33
30.
Hays GC,Mullard JE.Can nasal bacterial flora be predicted from clinical findings?.Pediatrics. 1972;49:596-9
31.
Wald ER.Purulent nasal discharge.Pediatr Infect Dis J. 1991;10:329-33
32.
Wald ER,Milmoe GJ,Bowen A, et al.Acute maxillary sinusitis in children.N Engl J Med. 1981;304:749-54
33.
Winther B.Effects on the nasal mucosa of upper respiratory viruses (common cold).Dan Med Bull. 1994;41:193-204
34.
Winther B,Brofeldt S,Gronborg H, et al.Study of bacteria in the nasal cavity and nasopharynx during naturally acquired common colds.Acta Otolaryngol (Stockh). 1984;98:315-20
35.
LaCroix JS,Ricchetti A,Lew D, et al.Symptoms and clinical and radiological signs predicting the presence of pathogenic bacteria in acute rhinosinusitis.Acta Otolaryngol. 2002;122:192-6
36.
Gwaltney JM,Scheld WM,Sande MA, et al.The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies.J Allergy Clin Immunol. 1992;90:457-61
37.
Hickner JM,Bartlett JG,Besser RE, et al.Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background.Ann Intern Med. 2001;134:498-505
38.
Gold SM,Tami TA.Role of middle meatus aspiration culture in the diagnosis of chronic sinusitis.Laryngoscope. 1997;107:1586-9
39.
Brook I,Frazier EH,Foote PA.Microbiology of chronic maxillary sinusitis: comparison between specimens obtained by sinus endoscopy and by surgical drainage.J Med Microbiol. 1997;46:430-2
40.
Benninger MS,Appelbaum PC,Denneny JC, et al.Maxillary sinus puncture and culture in the diagnosis of acute rhinosinusitis: the case for pursuing alternative culture methods.Otolaryngol Head Neck Surg. 2002;127:7-12
41.
Williams JW,Simel DL.Does this patient have sinusitis? Diagnosing acute sinusitis by history and physical examination.JAMA. 1993;270:1242-6
42.
Tiedjen KU,Becker E,Heimann KD, et al.Value of B-image ultrasound in diagnosis of paranasal sinus diseases in comparison with computerized tomography.Laryngorhinootologie. 1998;77:541-6
43.
de Bock GH,Houwing-Duistermaat JJ,Springer MP, et al.Sensitivity and specificity of diagnostic tests in acute maxillary sinusitis determined by maximum likelihood in the absence of an external standard.J Clin Epidemiol. 1994;47:1343-52
44.
Laine K,Maatta T,Varonen H, et al.Diagnosing acute maxillary sinusitis in primary care: a comparison of ultrasound, clinical examination and radiography.Rhinology. 1998;36:2-6
45.
Zinreich SJ.Rhinosinusitis: radiologic diagnosis.Otolaryngol Head Neck Surg. 1997;117:S27-34
46.
Leopold DA,Sod EW,Szeverenyi NM, et al.Clinical course of acute maxillary sinusitis documented by sequential MRI scanning.Am J Rhinol. 1994;8:19-28
47.
AmbrosePJonesRNVan WartS. Serial sinus aspirate sampling (SSAS): a novel technique for evaluating antimicrobial therapy of acute maxillary sinusitis (AMS) [presentation A-34]. Presented at the 43rd Inter-science Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL
48.
Dagan R,Klugman KP,Craig WA, et al.Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.J Antimicrob Chemother. 2001;47:129-40
49.
Gwaltney J,Syndor A,Sande M.Etiology and antimicrobial treatment of acute sinusitis.Otol Rhinol Layrngol. 1981;90:68-71
50.
Berg O,Carenfelt C,Kronvall G.Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment.Scand J Infect Dis. 1988;20:511-6
51.
Brook I.Microbiology and management of sinusitis.J Otolaryngol. 1996;25:249-56
52.
AnonJFergusonBWynneB. Pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily in the treatment of acute bacterial sinusitis (ABS) in adults [Poster #300]. Presented at the 41st Annual Meeting of the Infectious Disease Society of America; October 9–12, 2003; San Diego, CA
Wald ER,Reilly JS,Casselbrant M, et al.Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor.J Pediatr. 1984;104:297-302
55.
Faden H,Duffy L,Wasielewski R, et al.Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics.J Infect Dis. 1997;175:1440-5
56.
Faden H,Waz MJ,Bernstein JM, et al.Nasopharyngeal flora in the first three years of life in normal and otitisprone children.Ann Otol Rhinol Laryngol. 1991;100:612-5
57.
Muller-Graf CD,Whatmore AM,King SJ, et al.Population biology of Streptococcus pneumoniae isolated from oropharyngeal carriage and invasive disease.Microbiology. 1999;145:3283-93
58.
Faden H,Duffy L,Williams A, et al.Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life.J Infect Dis. 1995;172:132-5
59.
Faden H,Harabuchi Y,Hong JJ.Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media.J Infect Dis. 1994;169:1312-7
60.
PeltonSMarchantCDChristiansenDLoughlinA. Temporal changes in Serotype Distribution and Antimicrobial Resistance among isolates of S. pneumoniae in Massachusetts [presentation G-890]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL
61.
Bernstein JM,Dryja D,Murphy TF.Molecular typing of paired bacterial isolates from the adenoid and lateral wall of the nose in children undergoing adenoidectomy: implications in acute rhinosinusitis.Otolaryngol Head Neck Surg. 2001;125:593-7
62.
Dagan R,Leibovitz E,Greenberg D, et al.Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients.Pediatr Infect Dis J. 1998;17:880-5
63.
Ekdahl K,Ahlinder I,Hansson HB, et al.Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project.Clin Infect Dis. 1997;25:1113-7
64.
Chi DH,Hendley JO,French P, et al.Nasopharyngeal reservoir of bacterial otitis media and sinusitis pathogens in adults during wellness and viral respiratory illness.Am J Rhinol. 2003;17:209-14
65.
Scott JA,Hall AJ,Dagan R, et al.Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease.Clin Infect Dis. 1996;22:973-81
66.
Butler JC.Epidemiology of pneumococcal serotypes and conjugate vaccine formulations.Microb Drug Resist. 1997;3:125-9
67.
Joloba ML,Windau A,Bajaksouzian S, et al.Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.Clin Infect Dis. 2001;33:1489-94
68.
Dowell SF,Whitney CG,Wright C, et al.Seasonal patterns of invasive pneumococcal disease.Emerg Infect Dis. 2003;9:573-9
69.
Albanese BA,Roche JC,Pass M, et al.Geographic, demographic, and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore.Clin Infect Dis. 2002;34:15-21
70.
Appelbaum PC.Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae.Pediatr Infect Dis J. 1996;15:932-4
71.
Jacobs M,Appelbaum P.Antibiotic resistant pneumococci.Rev Med Microbiol. 1995;6:77-93
72.
Nagai K,Davies TA,Ednie LM, et al.Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.Antimicrob Agents Chemother. 2001;45:3242-5
73.
Fasola E,Bajaksouzian S,Appelbaum P, et al.Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae in four test methods.Anti-microb Agents Chemother. 1997;41:129-34
74.
Sutcliffe J,Grebe T,Tait-Kamradt A, et al.Detection of erythromycin-resistant determinants by PCR.Antimicrob Agents Chemother. 1996;40:2562-6
75.
Tait-Kamradt A,Davies T,Cronan M, et al.Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.Antimicrob Agents Chemother. 2000;44:2118-25
76.
Bozdogan B,Appelbaum PC,Kelly LM, et al.Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers.Clin Microbiol Infect. 2003;9:653-61
77.
Farrell DJ,Douthwaite S,Morrissey I, et al.Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study.Antimicrob Agents Chemother. 2003;47:1777-83
78.
Reinert RR,Wild A,Appelbaum P, et al.Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.Antimicrob Agents Chemother. 2003;47:2319-22
79.
Tait-Kamradt A,Davies T,Appelbaum PC, et al.Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.Antimicrob Agents Chemother. 2000;44:3395-401
80.
Kays MB,Wack MF,Smith DW, et al.Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation.Diagn Microbiol Infect Dis. 2002;43:163-5
81.
Musher DM,Dowell ME,Shortridge VD, et al.Emergence of macrolide resistance during treatment of pneumococcal pneumonia.N Engl J Med. 2002;346:630-1
82.
Butler JC,Lennox JL,McDougal LK, et al.Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy.Clin Infect Dis. 2003;36:e19-25
83.
Pihlajamaki M,Kataja J,Seppala H, et al.Ribosomal mutations in Streptococcus pneumoniae clinical isolates.Antimicrob Agents Chemother. 2002;46:654-8
84.
Depardieu F,Courvalin P.Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.Antimicrob Agents Chemother. 2001;45:319-23
85.
Gill MJ,Brenwald NP,Wise R.Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.Antimicrob Agents Chemother. 1999;43:187-9
86.
Felmingham D,Washington J.Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens—findings of the Alexander Project 1992-1996.J Chemother. 1999;11:5-21
87.
Ubukata K,Shibasaki Y,Yamamoto K, et al.Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.Antimicrob Agents Chemother. 2001;45:1693-9
88.
Peric M,Bozdogan B,Jacobs MR, et al.Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.Antimicrob Agents Chemother. 2003;47:1017-22
89.
Jacobs MR,Felmingham D,Appelbaum PC, et al.The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.J Antimicrob Chemother. 2003;52:229-46
Jacobs MR,Bajaksouzian S,Zilles A, et al.Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.Antimicrob Agents Chemother. 1999;43:1901-8
92.
JonesRNJohnsonDMSaderHSFritscheTR. Recent declines in β-lactam and MLSB resistance among S. pneumoniae and age-related effects: report from the SENTRY Antimicrobial Surveillance Program (North America, 1997-2002) [presentation C2-926]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL
93.
Hasegawa K,Yamamoto K,Chiba N, et al.Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States.Microb Drug Resist. 2003;9:39-46
94.
DaganRGreenbergDLeibermanA. The effect of azithromycin on carriage of antibiotic resistant S. pneumoniae in children depends on the prevalence of macrolide-resistance in the community [presentation G-898]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL
95.
Gonzales R,Bartlett JG,Besser RE, et al.Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods.Ann Intern Med. 2001;134:479-86
96.
Vogelman B,Gudmundsson S,Leggett J, et al.Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.J Infect Dis. 1988;158:831-47
97.
Craig W.Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.Clin Infect Dis. 1998;26:1-12
98.
CraigWAAndesDR. In vivo pharmacodynamic activity of faropenem against Streptococcus pneumoniae [abstract A-2094]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chicago, IL
99.
Craig WA,Andes D.Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.Pediatr Infect Dis J. 1996;15:255-9
100.
Craig WA.Antimicrobial resistance issues of the future.Diagn Microbiol Infect Dis. 1996;25:213-7
101.
Ambrose PG,Quintiliani R,Nightingdale CH, et al.Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia.Infect Dis Clin Pract. 1997;7:463-70
102.
Odenholt-Tornqvist I,Lowdin E,Cars O.Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.Antimicrob Agents Chemother. 1995;39:221-6
103.
CraigWAKiemSAndesDR. Free Drug 24-Hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin [abstract A-1264]. Presented at the 42nd Inter-science Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA
104.
Jackson M,Burry V,Olson L, et al.Breakthrough sepsis in macrolide resistant pneumococcal infection.Pediatr Infect Dis J. 1996;15:1049-51
105.
Leach A,Shelby-James T,Mayo M, et al.A prospective study of the impact of community-based arithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae.Clin Infect Dis. 1997;24:356-62
106.
Guggenbichler J,Kastner U.In influence of antibiotics on the normal flora.Infect Med. 1998;15 ((Suppl A)): 15-22
107.
Moore RD,Lietman PS,Smith CR.Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.J Infect Dis. 1987;155:93-9
108.
Preston S,Drusano G,Berman A, et al.Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials.JAMA. 1998;279:125-9
109.
Drusano GL,Johnson DE,Rosen M, et al.Pharmaco-dynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.Antimicrob Agents Chemother. 1993;37:483-90
110.
Lister PD,Sanders CC.Pharmacodynamics of moxifloxacin, levofloxacin, and sparfloxacin against Streptococcus pneumoniae.J Antimicrob Chemother. 2001;47:811-8
111.
Preston SL,Drusano GL,Berman AL.Levofloxacin population pharmacokinetic and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.Antimicrob Agents Chemother. 1998;42:1098-104
112.
Forrest A,Nix D,Ballow C.Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Anitmicrob Agents Chemother. 1993;37:1073-81
113.
Lacy MK,Lu W,Xu X, et al.Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.Antimicrob Agents Chemother. 1999;43:672-7
114.
Lister PD,Sanders CC.Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.J Antimicrob Chemother. 1999;43:79-86
115.
VesgaOCraigWA. Activity of levofloxacin against penicillin-resistant Streptococcus pneumoniae in normal and neutropenic mice. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15–18, 1996; New Orleans, LA
116.
Ambrose PG,Grasela DM,Grasela TH, et al.Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.Antimicrob Agents Chemother. 2001;45:2793-7
117.
Kim MK,Zhou W,Tessier PR, et al.Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model.Antimicrob Agents Chemother. 2002;46:3185-92
118.
VesgaOBonnatCCraigWA. In vivo pharmacodynamic activity of HMR3647, a new ketolide [abstract F-255]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada
119.
VesgaOAndesDCraigWA. Comparative in vivo activity of HMR 3647, azithromycin, clarithromycin and roxithromycin against S. pneumoniae and Staphylococcus aureus [abstract F-258]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada
120.
VesgaOCraigWA. Impact of macrolide resistance on the in vivo activity of a new ketolide, HMR 3647, against S. pneumoniae and S. aureus [abstract F-259]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada
121.
Zhanel GG,Walters M,Noreddin A, et al.The ketolides: a critical review.Drugs. 2002;62:1771-804
122.
AndesDVesgaOCraigW. Impact of neutrophils on the antimicrobial activity of ketolides in an animal infection model [abstract 1–19]. Presented at the Fourth International Conference on Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; January 21–23, 1998; Barcelona, Spain
123.
CapitanoBMaglioDBaneviciusMA. Bactericidal effect of cethromycin in an imunompetent murine pneumococcal pneumonia model [abstract A-1271]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27–30, 2002; San Diego, CA
124.
Tessier PR,Kim MK,Zhou W, et al.Pharmacodynamic assessment of clarithromycin in a murine model of pneumonia.Antimicrob Agents Chemother. 2002;46:1425-34
125.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard supplemental tables.NCCLS M7-A5/M100-S10 (M7). 2000;20:1-25
126.
Jacobs MR,Bajaksouzian S,Windau A, et al.Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.J Clin Microbiol. 2002;40:2369-3276
127.
Ambrose PG,Garsela DM.The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.Diagn Microbiol Infect Dis. 2000;38:151-7
128.
Dudley MN,Ambrose PG.Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.Curr Opin Microbiol. 2000;3:515-21
129.
Ambrose PG,Bhavnani SM,Cirincione BB, et al.Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.J Antimicrob Chemother. 2003;52:435-40
130.
Ambrose PG,Quintiliani R.Limitations of single point pharmacodynamic analysis.Pediatr Infect Dis J. 2000;19:769
131.
Nicolau DP,Ambrose PG.Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.Am J Med. 2001;111 ((Suppl 9A)): 13S-8
132.
Jones RN,Rubino CM,Bhavnani SM, et al.Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.Antimicrob Agents Chemother. 2003;47:292-6
133.
Schrag SJ,Pena C,Fernandez J, et al.Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial.JAMA. 2001;286:49-56
134.
Dagan R,Hoberman A,Johnson C, et al.Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with otitis media.Pediatr Infect Dis J. 2001;20:829-37
135.
Piglansky L,Leibovitz E,Raiz S, et al.Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children.Pediatr Infect Dis J. 2003;22:405-13
136.
File TM,Jacobs MR,Poole MD, et al.Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate.Int J Antimicrob Agents. 2002;20:235-47
137.
Doern GV.Activity of oral β-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.Otolaryngol Head Neck Surg. 2002;127:S17-23
138.
Powers JL,Gooch WM,Oddo LP.Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil, and azithromycin in pediatric patients.Pediatr Infect Dis J. 2000;19 ((12 Suppl)): S174-80
139.
Steele RW,Thomas MP,Begue RE.Compliance issues related to the selection of antibiotic suspensions for children.Pediatr Infect Dis J. 2001;20:1-5
Ambrose P,Owens R.New antibiotics in pulmonary critical care medicine; focus on advanced generation quinolones and cephalosporins.Semin Respir Crit Care Med. 2000;21:19-32
142.
Khaliq Y,Zhanel GG.Fluoroquinolone-associated tendinopathy: a critical review of the literature.Clin Infect Dis. 2003;36:1404-10
Urban C,Rahman N,Zhao X, et al.Fluoroquinolone—resistance Streptococcus pneumoniae associated with levofloxacin therapy.J Infect Dis. 2001;184:794-8
145.
Kays MB,Smith DW,Wack MF, et al.Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.Pharmacotherapy. 2002;22:395-9
146.
Ross JJ,Worthington MG,Gorbach SL.Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.N Engl J Med. 2002;347:65-6
147.
Dagan R,Leibovitz E,Fliss DM, et al.Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.Antimicrob Agents Chemother. 2000;44:43-50
148.
Doern GV.Antimicrobial use and emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.Clin Infect Dis. 2001;33 ((Suppl 3)): S187-92
149.
ChristiansonJAndesDRCraigWA. Pharmacodynamic characteristics of clindamycin against Streptococcus pneumoniae in a murine thigh-infection model [abstract A-1100]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chicago, IL
150.
Doern GV,Jones RN,Pfaller MA, et al.Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).Antimicrob Agents Chemother. 1999;43:385-9
151.
Doern GV,Heilmann KP,Huynh HK, et al.Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995.Antimicrob Agents Chemother. 2001;45:1721-9
152.
Bertho G,Gharbi-Benarous J,Delaforge M, et al.Conformational analysis of ketolide, conformations of RU 004 in solution and bound to bacterial ribosomes.J Med Chem. 1998;41:3373-86
153.
Capobianco JO,Cao Z,Shortridge VD, et al.Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae.Antimicrob Agents Chemother. 2000;44:1562-7
154.
CraigWAAndesDR. Pattern of bactericidal activity with telithromycin against erythromycin-resistant Streptococcus pneumoniae in the murine thigh-infection model [abstract A-2098]. Presented at the 41st Inter-science Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chicago, IL
155.
Bonnefoy A,Girard AM,Agouridas C, et al.Ketolides lack inducibility properties of MLS(B) resistance phenotype.J Antimicrob Chemother. 1997;40:85-90
156.
Agouridas C,Denis A,Auger JM, et al.Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.J Med Chem. 1998;41:4080-100
157.
Rosato A,Vicarini H,Bonnefoy A, et al.A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.Antimicrob Agents Chemother. 1998;42:1392-6
158.
Tessier PR,Mattoes HM,Dandekar PK, et al.Pharmacodynamic profile of telithromycin against macrolide and fluoroquinolone resistant Streptococcus pneumoniae in a neutropenic thigh infection model.Antimicrob Agents Chemother.. :
159.
DrusanoGLPrestonSL. Utility of an 800 mg dose of telithromycin for community-acquired pneumonia caused by extracellular pathogens: an assessment by pharmacodynamic modelling and monte carlo simulation [poster P1364]. Presented at: 12th European Congress of Clinical Microbiology and Infectious Disease; April 24–27, 2002; Milan, Italy
160.
Ferguson BJ.Recommendations for the treatment of acute bacterial rhinosinusitis are NOT based on current microbial resistance patterns.Otolaryngol Head Neck Surg. 2000;123:665-7
161.
Marchant C,Carlin S,Johnson C, et al.Measuring the comparative efficacy of antibacterial agents for acute otitis media: the “Pollyanna phenomenon.”.J Pediatr. 1992;120:72-7
162.
Poole MD.A mathematical therapeutic outcomes model for sinusitis.Otolaryngol Head Neck Surg. 2004;130:46S-50S
163.
Levine OS,Farley M,Harrison LH, et al.Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America.Pediatrics. 1999;103:E28
164.
Pallares R,Gudiol F,Linares J, et al.Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci.N Engl J Med. 1987;317:18-22
165.
Dagan R,Hoberman A,Johnson C, et al.Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media.Pediatr Infect Dis J. 2001;20:829-37
